RKTO
What one share of Rocket One holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT);
Rocket One’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.81 |
|---|---|
| Cash and investments | $0.34 |
| Book value | $0.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$12.40 | — | −$10.45 | — | $0.76 |
| 2019 | — | −$21.02 | — | −$13.50 | — | $5.92 |
| 2020 | — | −$14.56 | — | −$12.40 | — | $8.64 |
| 2021 | — | −$16.02 | — | −$13.54 | — | $10.30 |
| 2022 | — | −$9.50 | — | −$7.76 | — | $4.69 |
| 2023 | — | −$2.38 | — | −$2.48 | — | $2.19 |
| 2024 | — | −$1.28 | — | −$1.09 | — | $0.86 |
| 2025 | — | −$0.90 | — | −$0.71 | — | $0.40 |